실시간
FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitiesNINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxEndpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsIlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo FinanceFierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospectMIURA CO.,LTD.Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st
Endpoints News 2026년 1월 22일

High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’

High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’

본문을 이용할 수 없습니다. 원본 출처를 확인하세요.